Medicine and Dentistry
In Vitro
100%
Tumor Cell
100%
Ataxia Telangiectasia
100%
Lymphatic System Tumor
100%
PARP Inhibitor
100%
Olaparib
100%
B-Cell Chronic Lymphocytic Leukemia
13%
Programmed Cell Death
13%
Mantle Cell Lymphoma Cell Line
13%
Double-Strand DNA Break
13%
Neoplasm
6%
Lymphoblastoid Cell Line
6%
Xenograft
6%
Chronic Lymphocytic Leukemia
6%
Mantle Cell Lymphoma
6%
Prolymphocytic Leukemia
6%
Alkylating Antineoplastic Agent
6%
Poly ADP Ribose Polymerase
6%
Leukemia Cell Line
6%
Purine
6%
Cell Mutant
6%
Keyphrases
Tumor Cells
100%
Ataxia Telangiectasia mutated
100%
Lymphoid Tumors
100%
PARP Inhibitor (PARPi)
100%
Olaparib
100%
Mantle Cell Lymphoma
20%
Apoptosis
13%
DNA Double-strand Break Repair
13%
Lymphoma Cells
13%
Knockdown
13%
Chronic Lymphocytic Leukemia
6%
Lymphoblastoid Cell Lines
6%
DNA Damage
6%
Alkylating Agents
6%
Lymphoid Malignancies
6%
Improved Survival
6%
T-cell Prolymphocytic Leukemia
6%
Chronic Lymphocytic Leukemia Cells
6%
Mutant Cells
6%
In Vitro Sensitivity
6%
Leukemia Cells
6%
Leukemia Cell Lines
6%
Pharmacological Inhibitors
6%
Poly (ADP-ribose) Polymerase Inhibition
6%
Mitotic Catastrophe
6%
NOD-SCID
6%
AZD2281
6%
Murine Xenograft Model
6%
Purine Analogues
6%
Tumor Load
6%